KEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma Conference Paper uri icon

authors

  • Atkins, MB
  • Carlino, MS
  • Hill, AG
  • McNeil, CM
  • Ribas, A
  • Atkinson, V
  • Cebon, JS
  • Jameson, MB
  • Hwu, W-J
  • Thompson, JA
  • Anderson, J
  • Moreno, B Homet
  • Ibrahim, N
  • Long, GV

publication date

  • September 1, 2017